General Assembly leaders push for new plan to increase diversity in medical marijuana licenses

The president of the Maryland Senate is sponsoring a bill to increase diversity in medical marijuana grower licenses after a spate of other legislation addressing the issue has failed to gain traction in the Maryland General Assembly.

State lawmakers again consider legalization of marijuana

Supporters and opponents of legislation legalizing possession of up to two ounces of recreational marijuana were back in Annapolis to make their case before a state Senate committee.

Maryland Senate holds marijuana legalization hearing

Supporters and detractors alike gathered in Annapolis to testify about two marijuana legalization bills being heard by the Senate Judicial Proceedings Committee Thursday afternoon.

D.C. Pro-Marijuana Group Preps to Give Away Thousands of Joints on Inauguration Day

DCMJ is planning to protest President-elect Donald Trump’s stated opposition to federal legalization of marijuana by passing out over 4,200 joints at Friday’s inauguration.

Medical cannabis, justice, education top Black Caucus agenda

The Maryland Black Caucus laid out their priorities for the 2017 General Assembly session, including diversifying the medical cannabis industry, eliminating the cash bail system and reforming education during a press conference Wednesday morning.

Maryland patients still waiting on medical marijuana

Dispensaries are anticipated to open by next summer, but legal fights with the Natalie M. LaPrade Maryland Medical Cannabis Commission over licenses to grow the plant has many concerned that access will keep patients waiting longer.

Medical Marijuana Supporters Look for Change from Congress

The Senate passage of legislation allowing VA doctors to recommend medical marijuana use to their patients is a step in the right direction but medical marijuana supporters want to see a change in federal regulation.

Despite Dangers, Use of Synthetic Drugs Surges

More than 6,000 people have called poison control centers this year for problems related to taking a category of psychoactive drug known as synthetic cannabinoids. And that number is on the rise.